[go: up one dir, main page]

AR084728A1 - Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos - Google Patents

Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos

Info

Publication number
AR084728A1
AR084728A1 ARP110104306A ARP110104306A AR084728A1 AR 084728 A1 AR084728 A1 AR 084728A1 AR P110104306 A ARP110104306 A AR P110104306A AR P110104306 A ARP110104306 A AR P110104306A AR 084728 A1 AR084728 A1 AR 084728A1
Authority
AR
Argentina
Prior art keywords
poly
polyethylene glycol
lactic acid
active principles
preparation procedures
Prior art date
Application number
ARP110104306A
Other languages
English (en)
Inventor
Didier Bourissou
Abderrhamane Amgoune
Harivardhan Reddy Lakkireddy
Michel Veillard
Stephanie Greco
Serge Sable
Fethi Bensaid
Eric Didier
Didier Bazile
Original Assignee
Sanofi Sa
Centre Nat Rech Scient
Univ Toulouse 3 Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Centre Nat Rech Scient, Univ Toulouse 3 Paul Sabatier filed Critical Sanofi Sa
Publication of AR084728A1 publication Critical patent/AR084728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Peptides Or Proteins (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se refiere a conjugados de principios activos injertados a un polímero, a las nanopartículas que los comprenden, a su preparación y a sus intermedios.Reivindicación 1: Conjugado de un principio activo y de un copolímero de polietilenglicol y poli(ácido láctico) de fórmula (1), en la cual: mPEG es un metoxi-polietilenglicol; PLA es un poli(ácido láctico); m es el peso molecular medio del fragmento de polietilenglicol (mPEG), y está comprende entre 100 y 15.000 (expresado en Da); n es el peso molecular medio del fragmento de poli(ácido láctico), y está comprendido entre 1.000 y 50.000 (expresado en Da); AP es un resto de principio activo; L es un enlazador; X es un átomo de hidrógeno o un grupo alquilo opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos OR, CN, CF3, NRR’ y COOR, en donde R y R’, que son idénticos o diferentes entre sí, son un átomo de hidrógeno o un grupo alquilo; y sus sales farmacéuticamente aceptables.
ARP110104306A 2010-11-19 2011-11-18 Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos AR084728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059561A FR2967581B1 (fr) 2010-11-19 2010-11-19 Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques

Publications (1)

Publication Number Publication Date
AR084728A1 true AR084728A1 (es) 2013-06-05

Family

ID=43654132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104306A AR084728A1 (es) 2010-11-19 2011-11-18 Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos

Country Status (18)

Country Link
US (1) US9278137B2 (es)
EP (1) EP2640422B1 (es)
JP (2) JP6013354B2 (es)
AR (1) AR084728A1 (es)
CY (1) CY1119115T1 (es)
DK (1) DK2640422T3 (es)
ES (1) ES2625173T3 (es)
FR (1) FR2967581B1 (es)
HR (1) HRP20170691T1 (es)
HU (1) HUE032590T2 (es)
LT (1) LT2640422T (es)
PL (1) PL2640422T3 (es)
PT (1) PT2640422T (es)
RS (1) RS56021B1 (es)
SI (1) SI2640422T1 (es)
TW (1) TW201302225A (es)
UY (1) UY33741A (es)
WO (1) WO2012066117A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015422A1 (en) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2014106208A1 (en) * 2012-12-28 2014-07-03 Blend Therapeutics, Inc. Targeted conjugates encapsulated in particles and formulations thereof
ES2784423T3 (es) 2013-09-16 2020-09-25 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
KR20180112060A (ko) 2016-02-23 2018-10-11 타베다 세라퓨틱스, 인코포레이티드 Hsp90 표적화된 접합체 및 이의 입자 및 제형
CN112424178B (zh) * 2018-07-19 2025-01-28 星法马私人有限公司 治疗性树状聚体
CN110974972B (zh) * 2019-12-03 2023-01-20 沈阳药科大学 难溶性药物的弱酸性衍生物及其脂质体制剂
CN113933441A (zh) * 2021-09-30 2022-01-14 无锡紫杉药业有限公司 一种卡巴他赛及其中间体的测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
CN101701068B (zh) * 2009-10-30 2011-09-21 北京化工大学 一种pH响应性的Y型药物输送材料及其制备方法
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN103408710B (zh) * 2013-06-19 2015-12-23 北京化工大学 一种生物可降解及糖响应性的y型高分子药物输送材料及制备

Also Published As

Publication number Publication date
TW201302225A (zh) 2013-01-16
CY1119115T1 (el) 2018-02-14
ES2625173T3 (es) 2017-07-18
HRP20170691T1 (hr) 2018-05-18
JP2013542972A (ja) 2013-11-28
PT2640422T (pt) 2017-05-23
PL2640422T3 (pl) 2017-09-29
EP2640422B1 (en) 2017-03-01
JP2016172858A (ja) 2016-09-29
FR2967581B1 (fr) 2012-12-28
EP2640422A1 (en) 2013-09-25
RS56021B1 (sr) 2017-09-29
JP6013354B2 (ja) 2016-10-25
FR2967581A1 (fr) 2012-05-25
WO2012066117A1 (en) 2012-05-24
HUE032590T2 (en) 2017-10-30
SI2640422T1 (sl) 2017-10-30
JP6165920B2 (ja) 2017-07-19
US20130243719A1 (en) 2013-09-19
UY33741A (es) 2012-03-30
LT2640422T (lt) 2017-06-26
DK2640422T3 (en) 2017-05-22
US9278137B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
AR084728A1 (es) Conjugados polimericos de principios activos, sus procedimientos de preparacion y sus intermedios polimericos
WO2012131104A3 (en) Biodegradable compositions suitable for controlled release
EP2309989A4 (en) Polymerized Nanoparticles and Methods for Making and Using Them
CO6700831A2 (es) Derivados de pirazina como bloqueadores de enac
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
CY1123967T1 (el) Στερεη συνθεση για τη χορηγηση απο το στομα χρωστικων υλων και διαγνωστικη χρηση αυτης
CY1119829T1 (el) Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου
MX368966B (es) Conjugados de proteina-polimero-farmaco.
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1120492T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
HK1198629A1 (en) High-loading water-soluble carrier-linked prodrugs
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
GB2515233A (en) Conjugated polymers
NO20083573L (no) Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler
JP2012255007A5 (es)
ES2583928T3 (es) Copolímeros funcionales de PLA-PEG, las nanopartículas de los mismos, su preparación y uso para suministro dirigido de fármacos y formación de imágenes
MX2020000618A (es) Composicion farmaceutica.
NZ603939A (en) Conjugated blood coagulation factor viii
MX347056B (es) Composiciones farmaceuticas.
SV2011003907A (es) Composiciones antimicrobianas
BR112014024726A8 (pt) Polímeros, misturas de polímero, e artigos feitos a partir dos mesmos
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal